In the Claims:

3. (Amended) A compound according to claim 2 wherein R^2 is aryl, Het^1, C_{3-7}cycloalkyl, or C_{1-6}alkyl substituted with one or two substituents selected from hydroxy, cyano, amino, mono- or di(C_{1-4}alkyl)amino, C_{1-6}alkyloxy, C_{1-6}alkylsuslfonyloxy, C_{1-6}alkyloxycarbonyl, C_{3-7}cycloalkyl, aryl, aryloxy, arylthio, Het^1, Het^1oxy and Het^1thio; and if X is O, S or NR^3, then R^2 may also represent aminocarbonyl, aminothiocarbonyl, C_{1-4}alkylcarbonyl, C_{1-4}alkylthiocarbonyl, arylcarbonyl or arylthiocarbonyl.

4. (Amended) A compound according to claim 3 wherein the 6-azauracil moiety is in the para position relative to the central carbon atom.

5. (Amended) A compound according to claim 4 wherein q is 1 or 2 and one R^4 substituent is in the 4 position; and p is 1 or 2 and the one or two R^5 substituents are in the ortho position relative to the central carbon atom.

6. (Amended) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 1.

7. (Amended) A process for preparing a composition as claimed in claim 6, wherein a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as defined in claim 1.

Cancel Claims 8 and 9 without prejudice and add new Claims 13 and 14 as follows.

13. (New) A method for treating eosinophil-dependent inflammatory diseases in a warm-blooded animal in need thereof comprising administering to the warm-blooded animal an effective amount of a compound of Claim 1.

14. (New) The method of Claim 13, wherein the eosinophil-dependent inflammatory disease is selected from bronchial asthma, atopic dermatitis, allergic rhinitis or allergic conjunctivitis.